CSS
RPRX icon

Cubist Systematic Strategies’s Royalty Pharma RPRX Stock Holding History

Cubist Systematic Strategies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,776
Closed -$361K – 3488
2024
Q3 		$361K Buy
+12,776
New +$354K ﹤0.01% 2345
2024
Q2 		– Sell
-477,047
Closed -$14.5M – 3861
2024
Q1 		$14.5M Buy
477,047
+95,876
+25% +$2.83M 0.08% 315
2023
Q4 		$10.7M Buy
381,171
+166,723
+78% +$4.58M 0.07% 416
2023
Q3 		$5.82M Sell
214,448
-115,620
-35% -$3.43M 0.04% 656
2023
Q2 		$10.1M Buy
330,068
+307,854
+1,386% +$10.4M 0.07% 428
2023
Q1 		$800K Sell
22,214
-232,394
-91% -$8.62M ﹤0.01% 2357
2022
Q4 		$10.1M Buy
254,608
+132,176
+108% +$5.52M 0.06% 479
2022
Q3 		$4.92M Buy
122,432
+97,846
+398% +$4.18M 0.03% 1086
2022
Q2 		$1.03M Sell
24,586
-82,818
-77% -$3.4M 0.01% 2457
2022
Q1 		$4.18M Buy
107,404
+68,970
+179% +$2.71M 0.04% 861
2021
Q4 		$1.53M Sell
38,434
-50,206
-57% -$1.95M 0.01% 1605
2021
Q3 		$3.2M Sell
88,640
-123,848
-58% -$4.81M 0.04% 715
2021
Q2 		$8.71M Buy
212,488
+173,983
+452% +$7.4M 0.1% 271
2021
Q1 		$1.68M Buy
38,505
+27,729
+257% +$1.31M 0.02% 1164
2020
Q4 		$539K Sell
10,776
-56,889
-84% -$2.41M 0.01% 1733
2020
Q3 		$2.85M Buy
67,665
+64,919
+2,364% +$2.79M 0.04% 692
2020
Q2 		$133K Buy
+2,746
New +$136K ﹤0.01% 2145

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's RPRX Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 12,776 shares — an estimated $361K sold.

Cubist Systematic Strategies first reported a position in RPRX in Q2 2020 and held it in 17 quarters. The position peaked at $14.5M in Q1 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 12,776 Royalty Pharma shares in Q4 2024, an estimated $361K.
  • Cubist Systematic Strategies first reported a position in Royalty Pharma in Q2 2020 and held it in 17 quarters.
  • Cubist Systematic Strategies's Royalty Pharma position peaked at $14.5M in Q1 2024.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.